Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results

Viridian Therapeutics (NASDAQ:VRDN) issued its earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24, Zacks reports. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $15.53 on Friday. The business has a 50-day moving average of $18.20 and a 200 day moving average of $19.63. Viridian Therapeutics has a 12 month low of $11.40 and a 12 month high of $27.20. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.60 and a beta of 1.32. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Analysts Set New Price Targets

VRDN has been the subject of a number of recent research reports. Royal Bank of Canada raised their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. TD Cowen initiated coverage on Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a report on Monday, December 16th. Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.